News Search Results
Dec 18, 2025, 08:49 ET Participant Shares Results Following 5-Step Sleep Tantra Seminar on MyTSV.com
a critical public health concern. According to research published by the National Council on Aging, nearly 50% of older adults report symptoms of insomnia, significantly impacting their cognitive function and quality of life [1]. Addressing this widespread issue, MyTSV.com has released a compelling new
More news about: MyTSV
Dec 16, 2025, 08:00 ET Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
Symptoms of PPD include hallmarks of major depression, including, but not limited to, sadness, depressed mood, loss of interest, change in appetite, insomnia, sleeping too much, fatigue, difficulty thinking/concentrating, excessive crying, fear of harming the baby/oneself, and/or thoughts of death or suicide.
More news about: Lipocine Inc.
Dec 15, 2025, 11:01 ET Day & night: Cancer disrupts the brain's natural rhythm
release, reducing quality of life and increasing mortality.Disruptions to our own diurnal rhythms have been linked to stress responses like insomnia and anxiety—both common among cancer patients. The body depends on a feedback loop called the HPA axis to maintain healthy stress hormone levels.
More news about: Cold Spring Harbor Laboratory
Dec 05, 2025, 09:00 ET Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
than placebo) include transaminase elevations; somnolence; decreased appetite; diarrhea; pyrexia; vomiting; fatigue, malaise, and asthenia; rash; insomnia, sleep disorder and poor-quality sleep; and infections. Hematologic abnormalities were also observed.PREGNANCY:EPIDIOLEX should
More news about: Jazz Pharmaceuticals plc
Dec 04, 2025, 08:12 ET UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
trial, adverse reactions were generally similar to those observed and attributed to drug in adjunctive placebo-controlled trials, with the exception of insomnia (observed at a higher rate of ≥2%). Pediatric adverse reactions were similar to those seen in adult patients.Primary Generalized Tonic-Clonic
More news about: UCB
Dec 02, 2025, 17:31 ET Narcolepsy Market is Projected to Grow at a CAGR of 5.6% During the Forecast Period (2025-2034) Due to Increasing Disease Awareness, Improved Diagnosis, and Expanding Therapeutic Options | DelveInsight
Insomnia MarketInsomnia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key insomnia companies,
More news about: DelveInsight Business Research, LLP
Dec 02, 2025, 13:00 ET The VA Disability System Is Failing -- and Veterans Are Paying for the Gaps By Loren Ryan Hawley
VA disability program as an "honor system" heavily reliant on veterans self-reporting symptoms — particularly for conditions like PTSD, migraines, insomnia, chronic pain, depression, and Gulf War illnesses.Yet in reality, the VA often treats those same self-reports with skepticism:C&P
More news about: Odin Industries LLC
Dec 01, 2025, 09:00 ET Biocodex To Present New Data at the American Epilepsy Society (AES) 2025 Annual Meeting
more frequently than on placebo were somnolence, decreased appetite, agitation, ataxia, decreased weight, hypotonia, nausea, tremor, dysarthria, and insomnia.PREGNANCYThere are no adequate data on the developmental risks associated with the use of DIACOMIT in pregnant women. Based on
More news about: Biocodex, Inc.
Nov 25, 2025, 10:15 ET Dietary Supplements Market to Hit $414.5B by 2033, Growing at 8.9% CAGR - Key Trends & Insights by Grand View Research, Inc.
Detox/CleanseSkin/ Hair/ NailsSexual HealthBrain/Mental HealthInsomniaMenopauseAnti-agingPrenatal HealthOthersDietary
More news about: Grand View Research, Inc.
Nov 25, 2025, 09:29 ET CreatorFi Launches on Aptos with $2M Strategic Backing to Scale Stablecoin Credit for Creators
amplifying Aptos' mission to become the home for onchain finance and cross-border digital money movement.About CreatorFiCreatorFi, by Insomnia Labs, is a fintech platform that transforms digital media revenue into credit-ready assets, providing creators, studios, and media businesses
More news about: CreatorFi
Nov 25, 2025, 09:00 ET Insomnia Cookies Celebrates National Cookie Day with FREE Cookies for a Year
Download Insomnia Cookies images here.About Insomnia Cookies Insomnia Cookies is a rapidly expanding late-night bakery concept headquartered in Philadelphia, PA. Founded at the University of Pennsylvania by then-student Seth Berkowitz, Insomnia Cookies has been
More news about: Insomnia Cookies
Nov 25, 2025, 05:00 ET AI Detects First Imaging Biomarker of Chronic Stress
Chronic stress can affect both physical and psychological well-being, causing a variety of problems including anxiety, insomnia, muscle pain, high blood pressure and a weakened immune system, according to the American Psychological Association. Research shows that chronic stress
More news about: Radiological Society of North America (RSNA)
Nov 24, 2025, 08:56 ET Izzatov's Secret Rejuvenation Center Launches "5 Step Sleep Tantra": Revolutionary Sleep Restoration Method
individuals achieve rapid, deep, and restorative sleep. This systematic approach offers a powerful, long-term solution for those battling chronic insomnia, anxiety, and sleep deprivation. The "5-Step Sleep Tantra" moves beyond standard sleep hygiene advice. Developed by Master Izzatov, Founder
More news about: Izzatov's Secret Rejuvenation Center
Nov 21, 2025, 08:04 ET SK Life Science, Inc. to Present 10 Posters with New Cenobamate Data, Including a Late-Breaker, at the 2025 American Epilepsy Society (AES) Annual Meeting
dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes
More news about: SK Life Science, Inc.
Nov 19, 2025, 16:01 ET FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
fatal events in 0.2%. The most frequent neurologic toxicities were dysgeusia (34%), headache (17%), peripheral neuropathy (9%), dizziness (9%), and insomnia (8%). The incidence of signs and symptoms consistent with ICANS was 10% in IMDELLTRA®-treated patients including events with the preferred
More news about: Amgen
Nov 19, 2025, 09:00 ET Insomnia Cookies Marks 350 Locations in Ongoing Global Expansion
Download Insomnia Cookies images here. About Insomnia Cookies Insomnia Cookies is a category-disrupting late-night
More news about: Insomnia Cookies
Nov 18, 2025, 08:00 ET Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Symptoms of PPD include hallmarks of major depression, including, but not limited to, sadness, depressed mood, loss of interest, change in appetite, insomnia, sleeping too much, fatigue, difficulty thinking/concentrating, excessive crying, fear of harming the baby/oneself, and/or thoughts of death or suicide.
More news about: Lipocine Inc.
Nov 17, 2025, 08:04 ET SK Life Science, Inc. Announces Publication of C035 Study Analyses in Epilepsia and Seizure
dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes
More news about: SK Life Science, Inc.
Nov 13, 2025, 16:18 ET How to Talk to Your Doctor about CBD
of Medicine's comprehensive biomedical literature database. Start with broad terms like "cannabidiol" or "CBD," and refine with specifics such as insomnia, anxiety, aching joints, addiction. Filter for "clinical trials," "case reports," or "systematic reviews" to find specific types of evidence. Systematic
More news about: Fusion CBD Products
Nov 13, 2025, 10:15 ET Ingenus Pharmaceuticals Announces FDA Approval and Launch of First and Only Generic Equivalent to Premarin® Tablets (Conjugated Estrogens Tablets, USP)
levels. Most common adverse reactions (≥ 5 percent) are abdominal pain, asthenia, pain, back pain, headache, flatulence, nausea, depression, insomnia, breast pain, endometrial hyperplasia, leucorrhea, vaginal hemorrhage, and vaginitis. Please see full
More news about: Ingenus Pharmaceuticals LLC
Nov 12, 2025, 07:30 ET Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
meaningful changes on ophthalmic exams in the alixorexton-treated group. The most common TEAEs4,5 were pollakiuria, insomnia, urinary urgency, dizziness and headache. Approximately 95% of patients completed the eight-week double-blind portion of
More news about: Alkermes plc
Nov 12, 2025, 07:30 ET Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
meaningful changes on ophthalmic exams in the alixorexton-treated group. The most common TEAEs4,5 were pollakiuria, insomnia, urinary urgency, dizziness and headache. Approximately 95% of patients completed the eight-week double-blind portion of
More news about: Alkermes plc
Nov 12, 2025, 05:00 ET VISTAJET LAUNCHES THE SLEEP PROGRAM -- A SCIENCE-BACKED APPROACH TO REST AND RECOVERY AT ALTITUDE AND AT DESTINATION
performance to transform rest in-flight into a restorative advantage. As research continues to show that over one-third of adults experience insomnia[1] and over half experience poor sleep quality[2], VistaJet addresses a true demand for supportive travel solutions,
More news about: VistaJet
Nov 11, 2025, 16:24 ET Empower Mental Health & Wellness Clinic Opens Doors in Kenosha: Offering Mental Health Treatment and Physical Therapy
pain. As part of its launch, Empower will offer EXOMIND TMS, a noninvasive intervention to treat depression, reduce anxiety and food cravings, treat insomnia, and improve cognition and overall wellness.
More news about: Empower Mental Health & Wellness Clinic
Nov 10, 2025, 06:00 ET Headspace for Cigna Healthcare Enhances Everyday Mental Health Support Through Self-Guided, Science Backed Resources
depression symptoms after just 30 days. Participants in the Headspace Sleep Program also reported a 29% reduction in insomnia symptoms among adults with clinical, self-reported insomnia. Headspace and Cigna Healthcare will collaborate to develop custom content exclusively for Cigna customers.
More news about: Cigna Corporate Services, LLC